Arrowhead presents plozasiran data at AHA 2026 showing 78% lower acute pancreatitis event rate versus placebo

Arrowhead presented data at AHA 2026 showing plozasiran achieved a 78% lower acute pancreatitis event rate versus placebo with sustained triglyceride reductions, plus ARO-DIMER-PA lowering LDL cholesterol and triglycerides.

Detected & updated continuously · Source: Nebula